GlycoMantra received a SBIR Phase 1 grant from the NIDDK (NIH) June 03, 2020 GlycoMantra…
GlycoMantra has been awarded a two-year SBIR grant from the NIAID (NIH) to investigate COVID-19-impacted type 2 diabetes.
GlycoMantra has been awarded a two-year SBIR grant from the NIAID (NIH) to investigate COVID-19-impacted type 2 diabetes.